Patterns of antipsychotic prescription to patients with schizophrenia in korea: Results from the health insurance review & assessment service-national patient sample

Journal of Korean Medical Science

Volumn 29, Issue 5, 2014, Pages 719-728

  Park, Seon Cheol ^a,b   Lee, Myung Soo ^c   Kang, Seung Gul ^d   Lee, Seung Hwan ^e  

^a Yongin Mental Hospital   (South Korea)

^b Hanyang University   (South Korea)

^c Korea Suicide Prevention Center   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e Inje University   (South Korea)

Author keywords

Antipsychotics; Korea; Prescribing patterns; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL PRACTICE; DRUG COMBINATION; FEMALE; HEALTH INSURANCE; HUMAN; MALE; MIDDLE AGED; POLYPHARMACY; SCHIZOPHRENIA; SOUTH KOREA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; REPUBLIC OF KOREA; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84922392674     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.5.719     Document Type: Article

References (30)

1. Kwon JS, Kim ET, Ha TH, Roh KS, Choi JS, Kim YS. Drug prescribing patterns of outpatients with schizophrenia in a university hospital. J Korean Neuropsychiatr Assoc 2003; 42: 683-90.
2. Carpenter WT Jr, Davis JM. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry 2012; 17: 1168-73.
3. Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004; 58: 61-7.
4. Ahn YM, Kwon JS, Bahk WM, Kim CE, Park JI, Lee SY, Yi JS, Lee CH, Jang HS, Jun DI, et al. The feasibility test of Korean medication algorithm for the treatment with schizophrenic patients (II) : the problem for applying algorithm to the real clinical situation and opinion of revision. Korean J Psychopharmacol 2006; 17: 35-49.
5. Ahn YM, Lee HS, Kim YS, Kwon JS. Korean Medication Algorithm for Schizophrenia. In: Lee HS, editor. Clinical Neuropsychopharmacology. Seoul: ML Communications Co. Ltd., 2008, p731-42.
6. Choi HJ, Jung SH, Kang MH, Lee JS, Bae JN, Kim CE. Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean general hospital psychiatric unit: 2001 to 2008. Clin Psychopharmacol Neurosci 2011; 9: 17-22.
7. Shim IH, Woo YS, Jun TY, Kim KS, Bahk WM. Changes in antipsychotic drug usage in the psychiatric inpatients at a university hospital between 1997, 2003-2004 and 2009-2010. Korean J Psychopharmacol 2012; 23: 57-64.
8. Lee HJ, Lee TJ. Impact of price control on drug expenditure and factors associated with the drug switching among statins: analysis of HIRA-NPS data. Health Policy Manag 2013; 23: 112-23.
9. Ha JE, Bae JH. Reasons for extraction of permanent teeth in Korea. J Korean Acad Oral Health 2012; 36: 32-7.
10. Statistics Korea. Korean Standard Classification of Diseases. Seoul: Statistics Korea, 2010.
11. World Health Organization. The ICD-10 classification of mental and behavioural disorders, clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
12. Korean Index of Medical Specialties. Available at http://www.kimsonline.co.kr/051_Judge/genpricehistory.aspx [accessed on 1 July 2013].
13. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001; 62: 841-2.
14. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008; 100: 20-38.
15. Chang JG, Roh D, Kim CH. Recent trends of antipsychotics polypharmacy in schizophrenia. Korean J Psychopharmacol 2013; 24: 137-46.
16. Chung YK. Augmentation strategies for the treatment of schizophrenia. J Korean Soc Biol Psychiatry 1998; 5: 149-54.
17. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
18. Koranek AM, Smith TL, Mican LM, Rascati KL. Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. Schizophr Res 2012; 137: 137-40.
19. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2007; 163: 600-10.
20. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-23.
21. Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Shinfuku N, Yang SY, Chong MY, et al. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Aust N Z J Psychiatry 2011; 45: 968-75.
22. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168: 702-8.
23. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.
24. Chang SM, Cho SJ, Jeon HJ, Hahm BJ, Lee HJ, Park JI, Cho MJ. Economic burden of schizophrenia in South Korea. J Korean Med Sci 2008; 23: 167-75.
25. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080-9.
26. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, Markwick A, Lloyd H; CUtLASS team. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191: 14-42.
27. Yang J, Han C, Yoon HK, Pae CU, Kim MJ, Park SY, Ahn J. Experiences and barriers to implementation of clinical practice guideline for depression in Korea. BMC Psychiatry 2013; 13: 150.
28. Pilling S, Price K. Developing and implementing clinical guidelines: lessons from the NICE schizophrenia guideline. Epidemiol Psichiatr Soc 2006; 15: 109-16.
29. Hamann J, Ruppert A, Auby P, Pugner K, Kissling W. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 2003; 18: 237-42.
30. Jeong HG, Lee MS. Long-acting injectable antipsychotics in first-episode schizophrenia. Clin Psychopharmacol Neurosci 2013; 11: 1-6.